Clinical trial
Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent…
NCT00005861 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00005861 |
|---|---|
| Title | Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer |
| Official title | Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | pegylated liposomal doxorubicin hydrochloride |
| Start date | May 1, 2000 |
| Primary completion | Aug 1, 2005 |
| First posted | May 19, 2003 |
| Last update posted | Jun 10, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: